Introduction
Early clinical trials have demonstrated that, even using replicating vectors, the efficiency of gene delivery to tumours is currently very low. 1 Therefore, it is clear that genes with highly potent cytotoxic activity are required in order to obtain therapeutic levels of cell killing in vivo. To this end, we have been developing a new class of genes with both direct cytotoxic and immunostimulatory properties, called the fusogenic membrane glycoproteins (FMG). [2] [3] [4] FMG kill tumour cells by causing fusion between cells expressing the FMG and neighbouring cells which express the receptor for the viral fusogen. The fusogenicity of these proteins means that large local bystander effects can be achieved, where non-expressing cells can be recruited into large multi-nucleated syncytia Tyr-300 initiated expression of both the cytotoxic and the HSF-1 genes in melanoma cells. Gradual build up of HSF-1 amplified expression through binding to the HSE to give levels of cytotoxicity similar to that provided by a CMV promoter. However, no leakiness was observed in multiple nonmelanoma cell lines tested. In addition to amplifying low levels of weak tissue-specific expression, the use of HSF-1 also leads to activation of endogenous stress-related genes such as hsp70. Induction of these genes, in the presence of cell killing by the cytotoxic gene, is a highly immunostimulatory event which enhances the antitumour vaccination effects of direct tumour cell destruction. Having demonstrated the compatibility of the component elements in plasmid form, we incorporated the feedback loop into a hybrid LTR-modified retroviral vector and confirmed that the system can be effective in the form of a viral vector. The format of the feedback loop described here could be exploited for any tissue type in which a highly tissue-specific element can be identified but which is itself too weak to be effective therapeutically. Gene Therapy (2001) 8, 987-998. and eventually killed. Indeed, the bystander killing of the FMG in vitro is at least one log higher than that of the conventional suicide genes HSVtk or CD in most tumour cell lines tested so far. 2 In addition, expression of viral FMG is also highly immunostimulatory as judged by the immunogenicity of FMG-expressing vaccines and by the induction of stress-related proteins such as inducible heat shock proteins during the killing process. 2, 3 These dual properties of high local killing capacity and immunostimulatory activity make FMG attractive transgenes for use in gene therapy of cancer.
The ability to target gene expression to tumour cells is also an essential prerequisite for safe and effective gene therapy of cancer. This can be achieved by several different strategies, including surface targeting of the delivery vector and/or restriction of expression of the therapeutic gene(s) at the transcriptional level. In this respect, we and others have shown that the inclusion of tissue specific, inducible or even potentially tumour-specific transcriptional elements can be very effective at targeting gene expression to tumour cells of several different histological types. 5 However, the more potent the therapeutic gene that is used, the greater is the need for tight control of its expression to avoid toxicity. Therefore, the fact that many tissue-specific promoters are actually rather leaky in their expression profile will increasingly influence the ability to restrict potent cytotoxic genes to the appropriate tumour cell population. 5 During our experiments to use previously characterized transcriptional elements to target FMG expression to melanoma cells, 6, 7 we observed that the efficacy of transcriptional targeting is highly dependent upon the potency of the gene being used. We report here that elements which lead to 'phenotypic' tissue specificity of transgene expression with a GM-CSF therapeutic gene 7 are insufficient to control the expression of a much more potent FMG cDNA. Therefore, we have devised a transcriptional feedback loop based upon the identification of a minimal sequence of the human tyrosinase promoter 7, 8 which, by a sensitive nested polymerase chain reaction (PCR) protocol, is silent in non-melanoma cells but is active in melanomas. However, since the promoter is relatively weak, it must be used to initiate a feedback loop in melanoma cells which subsequently amplifies low level, but highly specific, gene expression. To achieve this, we have used a heat shock responsive element (HSE) 9, 10 upstream of the minimal melanoma-specific promoter. The HSE is bound by the heat shock factor-1 (HSF-1) transcription factor which is normally activated upon cell stress. 10, 11 We have used a mutant form of HSF-1, which is constitutively active even in the absence of stress, 12 cloned downstream of the FMG cDNA. We observed that low levels of expression from the tyrosinase promoter in melanoma cells initiates expression of both the FMG and the HSF-1 factor. FMG-mediated cell fusion itself activates expression of hsp70 which binds to the HSE and further increases the basal levels of expression. More importantly, low levels of HSF-1 expression feedback on the HSE upstream of the tyrosinase promoter and amplify expression of both the FMG and the HSF-1 proteins. This feedback loop has three principal advantages: (1) it leads to highly tissue-specific expression of a very potent cytotoxic gene; (2) it allows increasing levels of FMG to be expressed which will lead to very effective local tumour cell killing; and (3) it also leads to the expression of HSF-1 which transactivates endogenous HSE elements and leads to (melanoma cellspecific) expression of cellular stress proteins, including hsp70 and natural killer (NK) cell receptors. Our previous experiments, 13, 14 along with those of other groups, 15 have shown that induction of heat shock proteins (hsp) is a highly potent immune adjuvant to tumour cell killing 16 and leads to the generation of long-term antitumour immunity.
In summary, we describe here a novel transcriptional feedback loop which allows melanoma cell-specific expression of potent cytotoxic genes combined with an inherent immunostimulatory capacity to enhance tumour cell vaccination.
Results
Identification of an element of the human tyrosinase promoter that is transcriptionally silent in non-melanoma cells but retains activity in melanoma cell lines Previously we described a hybrid promoter/enhancer element in which three copies of the human tyrosinase distal element (TDE) 6, 17 were combined with the minimal SV40 promoter. 7 This element generated melanoma preferential expression of the GM-CSF transgene in the context of both plasmid and retroviral vector constructs. 7 However, when we cloned the cDNA of the GALV FMG 2,4 downstream of the TDE-SV40 element with the aim of generating melanoma-specific cell killing in vitro, although there was a clear lag period in the formation of syncytia compared with CMV-GALV, significant amounts of cell fusion subsequently developed after 72-96 h (data not shown). Since GALV has such a potent bystander killing effect 2, 3 it was clear that it would be necessary to improve the specificity of the transcriptional elements that are used to direct its expression. Therefore, we investigated whether it would be possible to identify an element within the human tyrosinase promoter 8 that would be transcriptionally silent in non-melanoma cells. We assayed fragments which ranged from +80 to −65, −115 or −300 from this basal promoter 8 using both CAT expression and rtPCR assays as a preliminary screen for expression. Both the 65 bp and the 115 bp fragments of the promoter showed some transcriptional activity by rtPCR in some, or all, of the non-melanoma cells tested (data not shown). In contrast, using a sensitive nested rtPCR, the 300 bp element of the tyrosinase promoter was transcriptionally silent in all of the non-melanoma cells tested but retained activity in the human and murine melanoma cells (Figure 1 ). However, when the CAT, GM-CSF or GALV genes were cloned downstream of the 300 bp promoter, levels of transgene expression were low, and melanoma cells transfected with the Tyr 300-GALV construct showed limited cell cytotoxicity at only about 10% of the levels produced by CMV-GALV (data not shown).
Amplification of low-level expression from a weak, but tissue-specific, promoter using a second transcriptional regulatory element Since these levels of expression are not therapeutic, even with highly potent genes such as the FMG, we devised a method to amplify gene expression from a genuinely tissue-specific, but weak, promoter. Previously, we have shown that tumour cells dying through GALV-mediated cell fusion induce hsp70 expression. 2, 3 Hsp70 is transcriptionally activated by binding of the HSF-1 transcription 11 to the HSE, a well-defined transcriptional element upstream of a variety of heat shock genes. 9, 10 We initially reasoned that by placing one or more HSE upstream of the weak Tyr-300 element, small levels of GALVmediated cell killing might induce endogenous HSF-1 as part of the stress response which would amplify expression from the HSE-Tyr-300 element. A consensus HSE sequence -5Ј-AGAATGTTCTAGAAG-3Ј modified from Goldenberg et al, 10 which has been reported to confer heat shock inducibility on reporter genes, was synthesized. 10, 12 In order to investigate whether it was necessary to optimize the topological spacing of the HSE element relative to any of the five characterized important DNA/protein binding sites within the 300 bp element of the tyrosinase promoter, 8 plasmids were made in which the HSE element was separated from the C nucleotide at position −300 of the Tyr-300 promoter by either no nucleotides or one full turn of the DNA helix (HSE-Tyr-300-FULL) or by a stuffer fragment representing one half turn of the helix (HSE-Tyr-300-HALF) (Figure 2a ). Both HSE-Tyr-300-GM-CSF plasmids transfected into MeWo melanoma cells produced the same low levels of GM-CSF (1) . Therefore, the HSE-Tyr-300 bp promoter is both tissue specific and can be induced by HSF-1d202-316.
Gene Therapy as the Tyr-300-GM-CSF plasmid (Figure 2b ). However, when the transfected cells were heat shocked at 42°C for 30 min, 24 h following transfection, GM-CSF production was increased, but only in cells transfected with the HSETyr-300 plasmids (Figure 2b) . Several experiments demonstrated up to a three-fold increase in GM-CSF production from melanoma cells transfected with the HSETyr-300-FULL construct compared with the HSE-Tyr-300-HALF construct (data not shown). The non-melanoma line HT1080 similarly treated did not produce any GM-CSF either with or without heat shock in vitro (data not shown). Similar results were obtained from rtPCR studies performed on melanoma and non-melanoma cells transfected with the HSE-Tyr-300-FULL or HSE-Tyr-300-HALF constructs, confirming both the tissue specificity of GM-CSF expression from melanoma cells, as well as the increased level of message using the HSE-Tyr-300-FULL construct (data not shown). Hence, the HSE element can co-operate with the Tyr-300 bp promoter to induce tissue-specific expression, an effect which can be optimized by engineering the topology of the spacing of the two separate elements.
Transcriptional transactivation of the HSE-Tyr-300 bp tissue-specific promoter is possible by mutant HSF-1 However, when the HSE-Tyr-300-FULL element was used to express the GALV FMG, transfection was unable to eradicate melanoma cells in vitro to the same extent as the CMV promoter (data not shown). Therefore, we devised a further modification, separate from the application of heat, to increase levels of expression from the tissue-specific HSE-Tyr-300-FULL element. The transcription factor HSF-1 normally exists as a monomeric protein which is neither able to traffic into the nucleus nor to activate transcription. However, on cellular stress, HSF-1 trimerises, translocates to the nucleus, binds HSE-like sequences and activates transcription of heat shock genes. 11 We exploited a deleted, mutant form of HSF-1, HSF-1d202-316, in which deletion of amino acids 202-316 removes the sensitivity to stress-dependent activation and nuclear translocation, 12 making it constitutively active in the absence of cellular stress while retaining the DNA and protein binding domains required to transactivate gene expression through the HSE. Therefore, coexpression of HSF-1d202-316 should be able to transactivate the very weak, but highly specific, HSE-Tyr-300 promoter ( Figure 3 ). When HSF-1d202-316 was co-transfected into MeWo melanoma cells along with the Tyr-300-GM-CSF construct, no GM-CSF production could be detected. However, when HSF-1d202-316 was co-transfected with the HSE-Tyr-300-FULL-GM-CSF construct, levels of GM-CSF were increased significantly to a level similar to that produced by heat shock (Figure 2b ). Importantly, co-transfection of HSE-Tyr-300-GM-CSF with HSF-1d202-316 into non-melanoma cells still gave no detectable GM-CSF production ( Figure 2b ). Therefore, even low levels of HSF-1d202-316 (as provided in a transient co-transfection assay) were capable of transactivating the HSE-Tyr-300 bp promoter element while retaining the tissue specificity of the tyrosinase promoter.
The HSE transcriptional control element can be used to transactivate gene expression from the melanomaspecific Tyr-300 promoter Based on these data, we reasoned that we could use the HSE-Tyr-300 transcriptional regulatory element, in tan-
Figure 3 The proposed HSE-Tyr-300-FMG-HSF-1 transcriptional feedback loop. Melanoma cells transduced by an HSE-Tyr-300-FMG-HSF1d202-316 vector will initially express only very low levels of both HSF-1 and FMG from the weak tyrosinase promoter (1). The expression of HSF-1 will subsequently feedback on the HSE-Tyr-300 element (2) to amplify the initially low levels of gene expression (3, 4). Over time, both HSF-1 and FMG expression will increase leading to therapeutic effects through FMG-mediated cell fusion. In addition, increasing levels of HSF1d202-316 will transactivate cellular heat shock protein promoters through endogenous HSEs which our previous work has demonstrated can be highly immunostimulatory for tumour cells (5). Since the Tyr-300 element is effectively silent in non-melanoma cells (see Figure 1), initiation of the feedback loop should not occur in such cell types.
dem with the HSF-1d202-316 transcription factor, to regulate highly tissue specific expression even of very potent cytotoxic genes ( Figure 3) . Moreover, such a strategy would have the additional therapeutic advantage that it should lead to tumour cell-specific expression of inducible hsps, such as hsp70, which we 13, 14 and others [18] [19] [20] [21] have previously shown to have very potent immunostimulatory properties in anti-tumour vaccination settings.
To confirm the operation of this feedback loop at the transcriptional level, murine B16 cells were co-transfected with HSE-Tyr-300-GALV and HSF-1d202-316 plasmids. Importantly, B16 cells are not fused by expression of the GALV FMG because they lack the Pit-1 receptor. rtPCR was used to follow expression of the transgenes ( Figure  4 ). The co-transfected HSF-1d202-316 was expressed within 24 h of transfection. However, the GALV transgene expressed from the HSE-Tyr element was not detected in appreciable amounts until 72 h following transfection ( Figure 4 ) presumably because sufficient levels of HSF-1d202-316 were required to build up in order to transactivate the HSE element. In the absence of cotransfected HSF-1d202-316 cDNA only very low or undetectable levels of mRNA for GALV were ever detected (data not shown). In addition, following the appearance of mRNA for the transfected HSF-1d202-316, transactivation of endogenous hsp70 was detected 24 h later. Once again, in the absence of co-transfected HSF-1d202-316 cDNA endogenous levels of hsp70 mRNA were never detected (data not shown). These data confirm both the operation of the feedback loop at the transcriptional level and the induction of endogenous heat shock and stress response genes. The latter induction will provide effective adjuvant functions for immunostimulation. 
g). Cells were harvested at time-points following transfection as shown and rtPCR was used to examine levels of expression of the GALV or HSF-1d202-316 transgenes and of endogenous murine hsp70 (details of primers available on request).
The HSE-Tyr-300/HSF-1 feedback loop can be used to kill melanoma cells specifically and efficiently To test the efficacy of the transcriptional feedback loop in vitro, the HSE-Tyr-300 GALV construct was transfected into non-melanoma human cells, Tel.CeB6 (Figure 5a , b) or HT1080 (data not shown). The only significant toxicity was seen in the cells transfected with the CMV-GALV construct (Figure 5a ). In contrast, both the HSE-Tyr-300 and Tyr-300-GALV constructs gave low levels of toxicity when transfected into a melanoma line, Mel624 ( Figure  5c , d) or similarly the MeWo line (data not shown). Quantitation of cell survival showed that the HSE-Tyr-300 construct gave small but significantly enhanced killing of Mel624 cells with respect to the Tyr-300 construct, presumably due to the proposed activation of the HSE-Tyr-300 element through induction of endogenous HSF-1 through GALV-mediated cell killing. However, greatly enhanced toxicity was observed with transfection of the HSE-Tyr-300-GALV constructs when the cells were either heat shocked or co-transfected with HSF-1d202-316 (Figure 5c, d) . That the latter effects were operative through HSF-1d202-316 regulation were confirmed by the demonstration that increasing amounts of co-transfected HSF-1d202-316 led to proportional increases in killing of melanoma cells, whereas no killing was observed with increasing concentrations of an irrelevant co-transfected ␤-Gal plasmid (Figure 5e, f) . Taken together, these data show that it is possible to control highly tissue-specific expression of the GALV FMG either through the application of heat itself, which could prove a valuable means of locoregional control of gene expression, 22, 23 or through co-expression of the HSF1d202-316 transcription factor. Co-expression of the HSE-Tyr-300-GALV and HSF-1 cDNAs prevents outgrowth of melanoma, but not nonmelanoma tumour xenografts Next, we wished to confirm that the expression levels of GALV produced by the feedback loop would be high enough to prevent the progression of human tumour xenografts in vivo. Transduction of Mel624 or HT1080 tumour cells with both the HSE-Tyr-300-GALV and HSF1d202-316 plasmids (under conditions in which between 1 and 2% of the tumour cells were transduced), was able to eradicate the progression of all the melanomas (10 of 10 animals tumour-free at 50 days after tumour seeding) ( Figure 6 ) whereas the non-melanoma tumours treated in the same way grew progressively (none of 10 animals tumour-free, 50 days following tumour seeding). In contrast, transduction of Mel624 or HT1080 tumour cells with CMV-␤-Gal DNA had no significant effect on tumour growth (one of 10 animals in each tumour type tumour-free 50 days following tumour seeding). Transduction with CMV-GALV was able to eradicate pro-gression of both tumour types but transduction of either tumour type with the HSE-Tyr-300 GALV plasmid in the absence of the HSF-1d202-316 cDNA had no antitumour effect, demonstrating that the HSF component is necessary for GALV expression to reach therapeutic levels. These data show that the expression of GALV from the HSE-Tyr promoter is sufficient to prevent the progression of human tumour xenografts in vivo in a melanomaspecific manner.
The complete HSE-Tyr-300-FMG-HSF-1 feedback loop can be incorporated within the context of a hybrid LTR retroviral vector Finally, to investigate whether the entire transcriptional feedback loop could be genetically linked, we cloned the HSE-Tyr-300 element into the 3ЈLTR of the MoMLVderived retroviral vector pBabe Puro. 24 The HSE-Tyr-300 enhancer/promoter was placed in the U3 region of the viral LTR using a strategy previously described in our laboratory, 7 in which the viral enhancer and promoter
Gene Therapy regions of the U3 region of the LTR are replaced with the heterologous enhancer/promoter elements (HSE-Tyr-300). Simultaneously, the GALV-FMG cDNA was cloned into the polylinker of the vector. As an added strategy to decrease the chances of initiating the feedback loop in non-melanoma cells, the HSF-1d202-316 cDNA was cloned downstream of the GALV cDNA, separated from it by a linker of 24 bp (Figure 7a ), thereby exploiting a strategy as described by Cosset et al. 25 Thus, the lack of an internal ribosome entry site (IRES) between the first (GALV) and the second (HSF-1d202-316) genes means that only a small proportion of the total mRNA molecules produced from the HSE-Tyr-300 promoter will undergo internal initiation of translation of the second transgene. 26 Hence, only those cells in which the promoter is sufficiently active will be able to generate enough mRNA such that any of the second gene is ever translated. Therefore, any non-melanoma cell, in which there is appreciable leakiness of the Tyr-300 element, should still have very low levels of expression of the feedback gene (HSF1d202-316), significantly reducing the chances of the feedback loop ever being initiated. Following packaging, reverse transcription and integration of the retroviral vector, an integrated provirus of structure shown in Figure  7a will be produced. Virus was packaged from the 293INT cell line with the VSV-G envelope and used to infect MeWo or Mel624 melanoma and HT1080, 293 or Tel non-melanoma cell lines. To confirm the correct operation of the feedback loop at the molecular level, Figure  7b shows rtPCR analysis for expression of the HSF1d202-316 mRNA following infection of melanoma or non-melanoma cells with various control and test viruses. Twenty-four hours after infection, HSF-1d202-316 mRNA was weakly detectable in both melanoma and non-melanoma cells infected with the pBabe GALV/HSF1d202-316 wtLTR virus but in neither cell line infected with the hybrid HSE-Tyr-300 LTR (data not shown). In contrast, at 72 h after infection, both cell lines expressed large amounts of HSF-1d202-316 mRNA from the wildtype LTR, but only the melanoma cell line expressed HSF-1d202-316mRNA following infection with the hybrid LTR vector. These data confirm that the HSE-Tyr-300 element is expressed from the retroviral vector hybrid LTR at high levels only in the melanoma cell line.
In addition, to demonstrate that the HSF-1d202-316 protein can truly be expressed from a vector of this design, cell lysates were prepared from melanoma and non-melanoma cells infected with retroviral vectors and probed by Western blotting for the presence of HSF-1d202-316 protein. Figure 7c shows that HSF-1d202-316 protein could be detected in both melanoma and non-melanoma cells infected with the pBabe GALV/HSF-1d202-316 a b wtLTR virus but only in the melanoma cells infected with the pBabe GALV/HSF-1d202-316 HSE-Tyr-300 LTR virus. These data confirm the rtPCR data showing melanoma-specific expression of mRNA from the hybrid LTR virus and confirm that the HSF-1d202-316 protein is expressed from the feedback loop with time. The ability of different packaged viral vectors to induce syncytia and cytotoxicity was followed with time ( Figure 7d , e). Whereas the control vector pBabe Puro generated no detectable syncytia in either melanoma or non-melanoma cell lines, the positive control vectors pBabe-GALV and pBabe GALV-HSF-1 (wt LTR), in which the GALV cDNA is driven by the MoMLV LTR, both induced syncytial formation within 24 h of infection of all cell types. This led to extensive cell killing over time. In contrast, the pBabe-GALV-HSF-1 (HSE-Tyr LTR) vector produced no detectable syncytia in either of the three non-melanoma cell lines, indicating that the LTR was unable to drive expression of the GALV cDNA. Of particular interest, no vector-induced syncytia were observed in infected 293 cells. These cells express the adenoviral E1A gene, which we and others have shown to transactivate expression of cellular hsp70 26 through the HSE element. However, despite constitutive transactivation of the HSE element, Gene Therapy the tissue specificity of the TYR-300 element was tight enough to prevent initiation of the feedback loop in these cells. However, in the two melanoma cell lines tested, syncytia were induced, but only 48-72 h following the appearance of syncytia with the wild-type LTR. Presumably this is due to the time lag required for the build up to sufficient levels of HSF-1d202-316 protein to transactivate the HSE element. Thereafter, syncytial development was very aggressive and the pBabe-GALV-HSF-1 (HSE-Tyr LTR) was able to kill over 90% of target melanoma cells, comparable to that of the wild-type LTRdriven GALV vector. Finally, to confirm that longer periods of culture did not allow pBabe-GALV-HSF-1 (HSETyr LTR) to induce syncytia, infected TelCeB6 cells were passaged for another week and inspected daily for syncytia. None were detected. Therefore, although there is a clear time delay in the ability of the pBabe-GALV-HSF-1 (HSE-Tyr LTR) vector to become effective, our data here demonstrate that it is both highly tissue specific and effective.
Figure 6 Co-expression of the HSE-Tyr-300-GALV and HSF-1 cDNAs prevents outgrowth of melanoma, but not non-melanoma tumor xenografts. Mel624 or HT1080 tumour cells were transduced with 10 g of plamsid DNA (CMV-GALV, CMV-␤-Gal or 10 g of both the HSETyr-300-GALV and HSF-1d202-316 plasmids together), complexed with Effectene lipid (Qiagen), and injected 4 h later subcutaneously into nude mice (10

Discussion
The use of tissue-specific promoters to drive therapeutic genes for cancer therapy involves two principal problems. The first is that many of the tissue-specific elements characterized to date are relatively weak compared with promoters such as the CMV promoter. This means that levels of therapeutic gene expression will be low. Coupled with the problems currently associated with poor efficiency of gene delivery, this represents a major barrier to effective therapy. The second problem is that few, if any, genuinely tumour-specific promoters exist and many tissue-specific promoters are, to differing extents, leaky. 5 Thus, the use of highly potent cytotoxic genes may be associated with toxicity to normal tissues if the vector is inadvertently delivered to cells surrounding the tumour.
To alleviate problems of low efficiency of gene delivery to tumours, we have developed the fusogenic membrane glycoproteins as a class of highly cytotoxic genes. [2] [3] [4] However, the FMG are so potent that expression of only a few molecules is sufficient to initiate fusion. Hence, even low levels of leakiness from the TDE-SV40 melanoma-specific promoter 7 were sufficient to cause marked cytotoxicity to a range of non-melanoma cell lines that we tested. These data indicated that the efficacy of transcriptional targeting with any specific promoter is directly related to the toxicity of the transgene being used. Hence, as more potent genes are being developed to compensate for deficiencies in gene delivery vectors, so more tightly regulated tissue-specific enhancer/ promoter elements will have to be co-developed.
Therefore, we established a feedback loop which is based upon amplification of gene transcription from a minimal element of the tysoinase promoter. 8 From three different promoter constructs (−300, −165 or −115 bp), we selected a 300 bp element of the human tyrosinase promoter that gave no detectable CAT expression or mRNA in all of the non-melanoma cell lines we tested. These data are consistent with the existence of a positive regulatory element in the tyrosinase promoter upstream of −165 which coincides with a binding site for a specific DNA binding factor. 8 However, although this 300 bp promoter expressed both CAT, GM-CSF and GALV FMG in Gene Therapy a melanoma lines, levels of expression were too poor for this element alone to be used therapeutically.
Figure 7 Structure of the integrated HSE-Tyr-300 hybrid LTR GALV-HSF-1d202-316 retroviral vector. (a) To construct the pBabe-GALV-HSF-1 (HSE-Tyr LTR) vector, the HSE-Tyr-300 element was cloned into the 3ЈLTR of pBabe Puro as described previously. 7 On viral packaging and reverse transcription the element is transferred into the 5ЈLTR from where it directs expression of the downstream GALV and HSF-1d202-316 cDNAs (see text for details). As controls for the experiments described below, the following vectors were also generated: pBabe Puro (no GALV or HSF-1cDNAs); pBabe-GALV-HSF-1 (wtLTR) -the same vector as pBabe-GALV-HSF-1 (HSE-Tyr LTR) except that the 3ЈLTR contains the wild-type viral enhancer and promoter elements; pBabe-GALV -pBabe Puro with the GALV cDNA driven by the wild-type MoMLV LTR. (b) Representative melanoma (Mel624) or non-melanoma (HT1080) cells were infected with 100 l of the following viruses: lane 1: pBabe Puro; lane 2: pBabe-GALV-HSF-1 (HSE-Tyr LTR); lane 3: pBabe-GALV-HSF-1 (wtLTR); lane 4: pBabe-GALV; lane 5: PBS. RNA was harvested from infected cultures at 72 h after infection and converted to cDNA. PCR was performed with primers specific to the HSF-1d202-316 RNA (200 bp). Equal loading in all lanes was verified using PCR for GAPDH (not shown). (c) Lysates from the cells infected as described in b above were blotted with an antibody to the mutant HSF-1d202-316 protein. HSF-1d202-316 protein was detectable in non-melanoma cells only when infected with the pBabe-GALV-HSF-1 (wtLTR) vector (lane 2) but not in cells infected with the pBabe-GALV-HSF-1 (HSE-Tyr LTR) virus (lane 3). In contrast, the mutant HSF-1d202-316 protein was detected abundantly from the melanoma-specific pBabe-GALV-HSF-1 (HSE-Tyr LTR) vector at 72 h after infection (lane 3) as well as from the wild-type LTR (at lower levels) (lane 2), showing that the design of the retroviral vector is effective at generating HSF-1 expression through the operation of the transcriptional feedback loop. (d) Time-course of syncytial development in a melanoma cell line (Mel624) and a non-melanoma cell line (TelCeB6) following infection with viral stocks. 292INT cells were transfected with the VSV-G envelope along with the different vectors as shown. Forty-eight hours later virus was
We had previously shown that cell fusion through GALV FMG expression induces hsp70 expression in tumour cells, 2,3 a fact which enhances the value of FMGmediated cell killing as an antitumour vaccination strategy.
16,18-21 Therefore, we reasoned that by placing the HSE DNA binding site upstream of the Tyr-300 element, low levels of GALV-induced cellular stress expression would positively feedback on the HSE to up-regulate FMG expression. We wished to position this HSE element in the correct topological position with respect to the DNA helix and any protein binding sites within the tyrosinase promoter with which the bound HSF-1 factor should interact. The 300 bp element of the human tyrosinase promoter contains at least four positive DNA binding elements as well as one negative element as described by Bentley et al. 8 Of particular importance is the M box (at −107 to −97), a conserved element found in other melanocyte-specific promoters. 8 However, we were uncertain as to which of these elements would mediate the crucial protein binding interactions with the HSF-1 factor binding to the HSE. Our data demonstrated that indeed the topology of the spacing of the HSE and the start of the 300 bp promoter made a significant difference in levels of expression from the hybrid enhancer/promoter construct. However, these results do not necessarily define, or optimise, the interactions between the tyrosinase promoter and the HSE element.
Although introduction of the HSE was effective, it still
Gene Therapy did not lead to levels of GALV expression required to kill large numbers of tumour cells in vitro. However, our data do demonstrate that it is possible to create a tissue-specific and heat inducible expression construct (Figures 2b  and 5 ). Recent reports of heat-regulated promoters derived from the hsp70 gene have demonstrated that heat induction of gene expression may be an interesting way to regulate locoregional gene expression for tumour therapy. 22, 23 Our data here show that the concept of heat inducibility can also be combined with tight tissue specificity and we are currently testing the HSE-Tyr constructs in this regard.
Therefore, we incorporated a mutant form of the HSF-1 transcription factor (HSF-1d202-316) into the strategy. 12 HSF-1d202-316 transactivated the HSE element and upregulated the otherwise low level of GALV expression. Interestingly, despite HSF-1d202-316 being expressed from a non-tissue-specific promoter in the co-transfection studies, GALV cytotoxicity was still observed only in melanoma cells. Thus, without the low level melanomaspecific activation of the Tyr-300 promoter, transactivation of the HSE element by HSF-1d202-316 was not sufficient to initiate non-melanoma cell transcription. Our experiments clearly demonstrate that this feedback loop works at the transcriptional level and leads to levels of cell killing of melanoma cells comparable to that achieved with the CMV promoter alone.
A further rationale for incorporating the HSF-1d202-316 factor is that it will also transactivate endogenous HSE elements upstream of cellular stress response genes -such as hsp70. We have shown that expression of HSF-1d202-316 in tumour cells induces expression of hsp70 as well as other potentially immunostimulatory genes. 16, [18] [19] [20] [21] Separate studies focused on gene transfer of HSF-1d202-316 as an immunotherapeutic strategy of itself will be reported elsewhere confirming that its expression, in the context of concomitant cell killing, is immunostimulatory (Gough et al, manuscript in  preparation) .
Finally, therefore, we incorporated the HSE-Tyr-300-element into a vector system in which both the FMG and the HSF-1d202-316 cDNAs are brought under the tissuespecific control afforded by the HSF-1d202-316-HSE feedback loop. We incorporated the HSE-Tyr-300 element into the 3ЈLTR of a retroviral vector in place of the viral enhancer to mimic the strategy we have previously described to obtain tissue-specific expression from retroviral vectors. 7 Following viral production, reverse transcription and integration the modified 3ЈLTR becomes the 5ЈLTR which directs expression of the GALV and HSF1d202-316 transgenes ( Figure 7a ). As an added safeguard for the generation of tissue-specific expression from the feedback loop, we separated the GALV and HSF-1d202-316 transgenes by a short linker rather than by an IRES element. The rationale is that derived from that described by Cosset and co-workers. 26 Because of a lack of an IRES between the first (GALV) and the second (HSF-1d202-316) genes, only a small proportion of the total transcribed mRNA molecules will undergo internal initiation of translation of the second transgene. Hence, only those cells in which the promoter is sufficiently active -that is melanoma cells -will generate enough mRNA such that any of the second gene is ever translated and the feedback loop will be initiated. Our data show that this is an effective strategy to confer very tight tissue-specific expression on GALV-mediated cytotoxicity within a Ctype retroviral vector. Compared with a normal MoMLV LTR driving GALV, cytotoxicity takes a significantly longer time to develop -presumably due to the need for the feedback loop to build up levels of the HSF-1d202-316 protein, but the final levels of cytotoxicity reached in melanoma cells were equivalent to the wild-type LTR. Most significantly, the HSE-Tyr-300 hybrid LTR gave no detectable cytotoxicity in non-melanoma cell lines even after extended periods of time.
Therefore, we have developed a positive feedback loop that relies on a highly tissue-specific element to initiate cell-type-specific transcription. By co-expressing the HSF1d202-316 transcription factor, low levels of tissuespecific expression build up eventually to levels that are as effective as the CMV promoter. This results in the melanoma-specific expression of a highly cytotoxic gene, and the induction of immunostimulatory genes through activation of the endogenous stress response, through transactivation by the HSF-1d202-316 transcription factor. This strategy therefore incorporates both transcriptional targeting, cytotoxic tumour cell killing and immune activation for antitumour therapy.
Materials and methods
Plasmids and cell lines
For the analysis of melanoma-specific gene expression, plasmids and viruses were transduced into either melanoma (MeWo, Mel624, A378M, B16 or 1735) or non-melanoma (HT1080; 293; Vero, Tel.CeB6, HeLa, CMT93) cell lines. The human tyrosinase promoter plasmids (300 bp, 115 bp or 65 bp) are as described by Bentley et al 8 and Diaz et al. 7 The TDE-SVO plasmid consists of three repeated copies of the 20 bp tyrosinase distal element (TDE) upstream of the minimal SV40 basal promoter (Promega). 7 The cDNA of the mutated HSF-1 transcription factor is described in Ref. 12 and consists of a deletion of the wild-type HSF-1 cDNA corresponding to amino acid positions 202-316. The HSE element -5Ј-AGAATGTTCTAGAAG-3Ј was synthesised as a consensus sequence which confers heat shock and HSF-1 responsiveness on heterologous genes as described. 9, 10 To assess promoter/enhancer strengths, plasmids were constructed using standard techniques such that different promoters and promoter/enhancer fragments were placed upstream either of the chloramphenicol acetyl transferase (CAT) gene, 7 the human GM-CSF gene 27 or the cDNA of the gibbon ape leukaemia virus fusogenic membrane glycoprotein (GALV-FMG).
2,4 Levels of gene expression were assayed using either CAT assays, 7 by measuring levels of human GM-CSF secreted from the plasmids by ELISA (Pharmingen, San Diego, CA, USA) or by semi-quantitative rtPCR as described below.
Hybrid LTR retroviral vectors were constructed from the parental MoMLV retroviral plasmid pBabe Puro. 24 Manipulations to the 3ЈLTR were made in the plasmid pSKLTR (a gift of Dr Rhys Jagger, ICRF, John Radcliffe Hospital, Oxford, UK, and Ref. 7) followed by reassembly into the pBabePuro plasmid through Cla1-Pvu1 ligations (as previously described 7 ). Full details of the cloning and plasmid maps are available on request.
Analysis of gene expression from cells by reverse transcriptase polymerase chain reaction RNA was prepared from cultured cell lines with the RNA Easy kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. RNA concentrations were measured and 1 g total cellular RNA was reverse transcribed in a 20 l volume using oligo-(dT) as a primer and Moloney murine leukaemia virus reverse transcriptase (Roche Molecular Biochemicals, Indianapolis, IN, USA). A cDNA equivalent of 1 ng RNA was amplified by the polymerase chain reaction using primers specific for the target genes (details of primers and PCR conditions for each gene are available on request). PCR was performed in a 50 l reaction mixture with 250 m of each dNTP, 100 nm of primers, 5 l of 10 × buffer (Applied Biosystems, Branchburg, NJ, USA) and 1 unit of super Taq DNA polymerase (Applied Biosystems) using 30 cycles. The reaction mix (25 l samples) was analysed by agarose gel electrophoresis (1%) in TAE buffer containing 0.2 g/ml ethidium bromide. In all experiments, a mock PCR (without added DNA) was performed to exclude contamination. To exclude carry over of genomic DNA during the RNA preparation step, controls were also carried out in which the reverse transcriptase enzyme was omitted.
Detection of HSF-1d202-316 protein by Western blotting Protein samples were harvested from log-phase cells in 20 mm Tris-HCl buffer (pH 7.5) containing 1% v/v triton-X 100, 0.05% w/v SDS, 5 mg/ml w/v sodium deoxychol-ate, and 150 mm NaCl, including a protease inhibitor cocktail (Biorad, Hercules, CA, USA). Protein concentration was estimated using a Biorad Protein Estimation System. Ten g protein was heated at 95°C for 5 min in loading buffer to a final concentration of 0.1 m Tris-HCl, 2% v/v glycerol, 2% w/v SDS, 1% v/v beta-mercaptoethanol, and 0.01% w/v bromophenol blue. Samples were separated on a 12% SDS PAGE gel and blotted to Hybond ECL nitrocellulose membrane (Amersham, UK) by semidry transfer. Nonspecific binding was blocked in 10% w/v powdered milk in TBS containing 0.05% v/v Tween-20 (TBS-T) for 1 h at room temperature. Membranes were probed overnight at 4°C with a rabbit monoclonal anti-HSF-1 (SPA-901; StressGen, Victoria, BC, Canada) in antibody diluent (1% w/v powdered milk in TBS-T), washed in TBS-T, and probed for 1 h with anti-rabbit HRP (NA-934; Amersham) and extensively washed in TBS-T. Enzyme binding was detected using Supersignal West Pico Chemiluminescent Substrate (Pierce, Rockford, IL, USA) and exposure to X-OMAT-AR film (Amersham).
Cell transfection and FMG-mediated cell killing assays
To assess the cytotoxicity of the GALV FMG driven by the HSE-Tyr-300, Tyr-300 or the CMV promoters, cells were plated in six-well plates at a density of 5 × 10 5 cells per well. Twenty-four hours later, each well was transfected with 5 g of the appropriate plasmid DNA using calcium phosphate transfection (Profection; Promega, Madison, WI, USA) according according to the manufacturer's instructions. Four hours later the cells were washed three times in serum-free medium and then incubated in normal, serum-containing medium for a further 72 h. Plates were either counted for living cells to assess the levels of cell survival 2 or were stained with Crystal violet as a pictorial representation of the degree of cytotoxicity. To determine the heat shock sensitivity of the HSE element, the appropriate plates were sublethally heat shocked at 42°C for 30 min.
In vivo studies All procedures were approved by the Institutional Animal Care and Use Committee at the Mayo Foundation. Athymic nude mice were injected with 10 6 tumour cells to establish subcutaneous tumours. Animals were examined daily until tumour became palpable and killed if tumour size reached 1.0 × 1.0 cm. An individual mouse was considered tumour free if the tumour was less than 0.3 × 0.3 cm.
Generation of retroviral vector stocks
The GALV FMG cDNA was subcloned into the pBabePuro 24 vector backbone at the EcoRI sites in the polylinker using standard techniques. Subsequently, the cDNA for the HSF-1d202-316 transcription factor 12 was subcloned downstream of the GALV cDNA into the SalI site of the pBabePuro polylinker leaving a 24 bp linker to separate the GALV and HSF-1d202-316 genes (see Results for more details). This C-type vector was packaged into viral particles by transfection of 5 g of plasmid DNA into the 293INT cell line which stably expresses the MoMLV gag and pol genes but no envelope (a gift from F Loic-Cosset, INSERM U412, Lyon, France) along with 5 g of the plasmid pMD.G encoding the VSV-G envelope protein. 28, 29 Transfections were carried out in a 10 cm plate out using the Profection (calcium phosphate co-precipitation)
Gene Therapy method (Promega). Forty-eight to 72 h following transfection, cell supernatants were recovered, filtered through a 0.45 m filter and either used directly for infection or frozen at −80°C. Viral titres were routinely produced at a level of greater than or equal to 2 × 10 4 infectious units per ml by this method. Viral infections were performed by exposing exponentially growing target cells (either melanoma, Mel624 or MeWo) or non-melanoma (HT1080, 293 or TelCeB6), to different dilutions of viral supernatants in serum-free medium for 4 h in 24-well plates. The infectious medium was then removed and cells were washed three times before being allowed to grow in normal growth medium for a further 120 h. At this stage, infected cultures were counted for living cells to assess the levels of cell survival. 2 
